RYTM
HEALTHCARERhythm Pharmaceuticals Inc
AI Insight
What's Moving RYTM Today?
No stock-specific AI insight has been generated for RYTM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$60.80$122.20
$106.19
Fundamentals
Market Cap$7.2B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-101.2%
Profit Margin-93.3%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding68.6M
RYTM News
22 articles- Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?Yahoo Finance·Jun 22, 2026
- Rhythm Pharmaceuticals posts long-term setmelanotide data for obesityProactive Investors·Jun 16, 2026
- The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingYahoo Finance·Jun 15, 2026
- Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026Yahoo Finance·Jun 15, 2026
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026Yahoo Finance·Jun 13, 2026
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeYahoo Finance·Jun 12, 2026
- How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis AlgorithmYahoo Finance·Jun 8, 2026
- Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026GlobeNewswire Inc.·May 29, 2026
- Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsYahoo Finance·May 28, 2026
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesYahoo Finance·May 26, 2026
- Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyYahoo Finance·May 12, 2026
- A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter ResultsSimply Wall Street·May 11, 2026
- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearYahoo Finance·May 8, 2026
- Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceYahoo Finance·May 6, 2026
- Why Rhythm Pharmaceuticals Stock Triumphed on TuesdayMotley Fool·May 6, 2026
- Rhythm Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth PotentialYahoo Finance·May 5, 2026
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 5, 2026
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateYahoo Finance·May 5, 2026
- How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE ExpansionYahoo Finance·May 4, 2026
- Rhythm Pharmaceuticals Announces Changes to Board of DirectorsGlobeNewswire Inc.·Apr 3, 2026
All 22 articles loaded
Price Data
Open$101.00
Previous Close$106.19
Day High$107.00
Day Low$99.49
52 Week High$122.20
52 Week Low$60.80
52-Week Range
$60.80$122.20
$106.19
Fundamentals
Market Cap$7.2B
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-101.2%
Profit Margin-93.3%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding68.6M
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—